Cenk Tek, MD
Professor of PsychiatryCards
About
Research
Overview
Medical Research Interests
Diseases; Health Care; Memory; Obesity; Psychiatry; Psychiatry and Psychology; Schizophrenia
Publications
2024
Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial.
Grilo C, Ivezaj V, Tek C, Yurkow S, Wiedemann A, Gueorguieva R. Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial. American Journal Of Psychiatry 2024 PMID: 39659158, DOI: 10.1176/appi.ajp.20230982.Peer-Reviewed Original ResearchCognitive-behavioral therapyBinge-eating disorderEffectiveness of cognitive-behavioral therapyBinge-eating remission ratesEating-disorder psychopathologyCognitive behavioral therapyEvidence-based treatmentsRemission ratePercent weight lossHigher remission ratesBinge-eating frequencyBehavioral therapyPosttreatment assessmentLisdexamfetamineRandomized controlled trialsHeightened ratesCostly public health problemIntention-to-treat ratesFunctional impairmentWeight lossControlled trialsDisordersPosttreatmentIndividualized treatmentMixed modelsLisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: randomized double-blind placebo-controlled trial
Grilo C, Ivezaj V, Yurkow S, Tek C, Wiedemann A, Gueorguieva R. Lisdexamfetamine maintenance treatment for binge-eating disorder following successful treatments: randomized double-blind placebo-controlled trial. Psychological Medicine 2024, 54: 3334-3344. PMID: 39258475, PMCID: PMC11496227, DOI: 10.1017/s003329172400148x.Peer-Reviewed Original ResearchEating-disorder psychopathologyBinge-eating disorderMaintenance treatmentAcute treatmentBinge-eating remission ratesCognitive-behavioral therapyEfficacy of lisdexamfetamineSignificant weight gainDouble-blind placebo-controlled trialAcute respondersLisdexamfetamine treatmentPsychopathological outcomesPosttreatment assessmentLisdexamfetaminePlacebo-controlled trialRandomized double-blind placebo-controlled trialSingle-site trialAssociated with significant weight lossPsychopathologyBinge-eatingRemission rateWeight lossPlaceboRelapse rateControl researchThe impact of early detection (ED) campaigns on care presentations: Beyond DUP reduction
Hazan H, Ferrara M, Riley S, Li F, Zhou B, Kline E, Gibbs-Dean T, Karmani S, Tayfur S, Tek C, Keshavan M, Srihari V. The impact of early detection (ED) campaigns on care presentations: Beyond DUP reduction. Schizophrenia Research 2024, 264: 457-461. PMID: 38266513, PMCID: PMC10923115, DOI: 10.1016/j.schres.2024.01.022.Peer-Reviewed Original ResearchConceptsCoordinated specialty careDuration of untreated psychosisImpact of early detectionEarly detectionEarly detection campaignsSpecialty careAdjustment scoresCampaign yearDetection campaignsMediation analysisEffects of EDRegression modelsCareUntreated psychosisPositive symptomsGAFPatientsSalutary effects
2023
The effect of duration of untreated psychosis (DUP) on the risk for hospitalization after admission to a first episode service
Ferrara M, Guloksuz S, Hazan H, Li F, Tek C, Sykes L, Riley S, Keshavan M, Srihari V. The effect of duration of untreated psychosis (DUP) on the risk for hospitalization after admission to a first episode service. Schizophrenia Research 2023, 260: 198-204. PMID: 37688984, DOI: 10.1016/j.schres.2023.08.005.Peer-Reviewed Original ResearchConceptsFirst-episode psychosis servicesLength of stayUntreated psychosisPsychiatric hospitalizationFirst-episode servicesDuration of hospitalizationIncidence rate ratiosNon-affective psychosisNew Haven areaPoisson regression modelsPatient characteristicsHospitalization ratesRecent onsetMedical recordsHospitalizationEffect of durationNegative binomial regressionSpecialized treatmentPsychosisRate ratioBinomial regressionAdmissionDUPEnrollmentFirst year
2022
Corrigendum to: Reducing the Duration of Untreated Psychosis (DUP) in a US Community: A Quasi-Experimental Trial
Srihari V, Ferrara M, Li F, Kline E, Gülöksüz S, Pollard J, Cahill J, Mathis W, Sykes L, Walsh B, McDermott G, Seidman L, Gueorguieva R, Woods S, Tek C, Keshavan M. Corrigendum to: Reducing the Duration of Untreated Psychosis (DUP) in a US Community: A Quasi-Experimental Trial. Schizophrenia Bulletin Open 2022, 3: sgac020. PMID: 39144776, PMCID: PMC11206056, DOI: 10.1093/schizbullopen/sgac020.Peer-Reviewed Original Research
2020
O1.2. REDUCING THE DURATION OF UNTREATED PSYCHOSIS IN A U.S. CATCHMENT: THE MINDMAP CAMPAIGN
Srihari V, Ferrara M, Kline E, Li F, Burke S, Cahill J, Guloksuz S, Woods S, Tek C, Keshavan M. O1.2. REDUCING THE DURATION OF UNTREATED PSYCHOSIS IN A U.S. CATCHMENT: THE MINDMAP CAMPAIGN. Schizophrenia Bulletin 2020, 46: s1-s1. PMCID: PMC7233978, DOI: 10.1093/schbul/sbaa028.001.Peer-Reviewed Original Research
2019
31.1 COMBINING EXERCISE PHYSIOLOGY, RECREATIONAL THERAPY, VIRTUAL REALITY GAMING TECHNOLOGY, AND PSYCHOSOCIAL REHABILITATION TO PROMOTE PHYSICAL EXERCISE IN SERIOUS MENTAL ILLNESS
Choi J, Taylor B, Fiszdon J, Astur R, Haber L, Shagan D, Tek C, Kurtz M, Pearlson G. 31.1 COMBINING EXERCISE PHYSIOLOGY, RECREATIONAL THERAPY, VIRTUAL REALITY GAMING TECHNOLOGY, AND PSYCHOSOCIAL REHABILITATION TO PROMOTE PHYSICAL EXERCISE IN SERIOUS MENTAL ILLNESS. Schizophrenia Bulletin 2019, 45: s139-s140. PMCID: PMC6455379, DOI: 10.1093/schbul/sbz022.127.Peer-Reviewed Original ResearchEffects of Curcumin on Cognitive Functioning and Inflammatory State in Schizophrenia
Kucukgoncu S, Guloksuz S, Tek C. Effects of Curcumin on Cognitive Functioning and Inflammatory State in Schizophrenia. Journal Of Clinical Psychopharmacology 2019, 1. DOI: 10.1097/00004714-900000000-98602.Peer-Reviewed Original Research
2017
Alpha‐lipoic acid (ALA) as a supplementation for weight loss: results from a meta‐analysis of randomized controlled trials
Kucukgoncu S, Zhou E, Lucas K, Tek C. Alpha‐lipoic acid (ALA) as a supplementation for weight loss: results from a meta‐analysis of randomized controlled trials. Obesity Reviews 2017, 18: 594-601. PMID: 28295905, PMCID: PMC5523816, DOI: 10.1111/obr.12528.Peer-Reviewed Original ResearchConceptsAlpha-lipoic acidBody mass indexAlpha-lipoic acid treatmentPlacebo groupWeight lossEffect of ALASignificant short-term weight lossShort-term weight lossModest weight lossPlacebo treatment groupsPlacebo-controlled studyWeight changeAnti-obesity propertiesSystematic literature searchMeta-regression analysisMass indexSignificant morbidityALA doseBMI changeLong-term benefitsWeight managementBMI differencesTreatment groupsMortality rateStudy duration178.3 Mindmap: A Population-Based Approach to Early Detection of Psychosis in the United States
Srihari V, Guloksuz S, Li F, Tek C, Woods S, Pollard J, Cahill J, Keshavan M, Seidman L. 178.3 Mindmap: A Population-Based Approach to Early Detection of Psychosis in the United States. Schizophrenia Bulletin 2017, 43: s95-s95. PMCID: PMC5475714, DOI: 10.1093/schbul/sbx021.255.Peer-Reviewed Original Research
Clinical Trials
Current Trials
Treatments to Treat Loss-of-Control Eating and Improve Weight Outcomes after Bariatric Surgery
HIC ID2000029057RoleSub InvestigatorPrimary Completion Date11/30/2027Recruiting Participants
Clinical Care
Overview
Cenk Tek, MD, is a psychiatrist with a focus on treating individuals with psychotic disorders. He specializes in treating conditions such as schizophrenia and bipolar disorder, providing a comprehensive range of treatments that include medication management and psychosocial interventions designed to stabilize symptoms and promote long-term recovery.
Dr. Tek’s research involves exploring the most effective treatments for psychotic disorders. He has been involved in developing and refining early intervention services for individuals experiencing their first episode of psychosis, and he works on improving clinical outcomes for these patients.
Dr. Tek received his medical training from Hacettepe University Faculty of Medicine in Turkey. He completed his residency and psychiatry fellowship at Yale School of Medicine.
Clinical Specialties
Psychiatry
News
News
- December 11, 2024Source: The American Journal of Psychiatry
Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial
- October 24, 2024Source: Cambridge University Press
Lisdexamfetamine Maintenance Treatment for Binge-Eating Disorder Following Successful Treatments
- February 13, 2024Source: WNPR
Mindmap 2.0 on Connecticut Public Radio
- June 15, 2021
Connecticut Mental Health Center Announces Faculty Appointments
Get In Touch
Contacts
Locations
Connecticut Mental Health Center
Academic Office
34 Park Street, Ste Rm. 267E
New Haven, CT 06519